Overview

An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Cetuximab